Main Content



If you find any errors or omissions in these Guidelines, or feel that something in them needs to change, write to:

Please include details of the page on which you wish to provide feedback.

Thank you for your assistance in ensuring that these Guidelines are up to date and correct.

Search again


This guidance applies to applicants Sarcoidosis affecting any organ system, whether active or quiescent.

Aeromedical Implications 

Effect of aviation on condition

  • Fatigue
  • Sleep deprivation
  • Increased cardiac workload during stressful phases of flight
  • Hypoxic, hypobaric, low relative humidity flight environment

Effect of condition on aviation

  • Overt incapacitation
    • Distracting pain
    • Acute shortness of breath
    • Pulmonary embolism
    • Heart failure
    • Arrhythmia
    • Seizure
    • Sudden death
  • Cognitive impairment
  • Vision impairment
  • Fatigue

Effect of treatment on aviation

  • Neuropsychological impairment secondary to steroid treatment
  • Risk of infection

Approach to medical certification

Based on the condition

  • Confirmed diagnosis
  • Absence of significantly impaired respiratory, ocular, neurological, renal or cardiac involvement
  • Reports and investigations will be dependent upon if primarily pulmonary sarcoidosis or if there is extrapulmonary involvement

Based on Treatment

  • Acceptable, stable treatment without significant side effects

Demonstrated Stability

  • Adequate period of grounding before new aviation medical assessment until demonstrated stability and absence of symptoms or complications
  • Absence of symptoms eg shortness of breath


Risk assessment protocol - Information required

New cases

CASA requires a report from the treating specialist(s) – eg. Respiratory physician, Cardiologist, Ophthalmologist etc, depending on organ involvement. The report(s) should detail:

  • Confirmed diagnosis
  • Clinical status
    • symptoms such as breathlessness, pain, palpitations, visual disturbance, neurological symptoms, etc
    • progress
  • Investigation reports (for relevant affected organ systems)
    • Respiratory:
      • chest x-ray
      • spirometry
      • histopathology report
      • blood test results
      • If clinically indicated, full pulmonary function testing, diffusion capacity, blood gases
    • Cardiac:
      • ECG
      • Echocardiogram with ejection fraction
      • 24 or 48 hour Holter
      • If clinically indicated, stress test
    • Ophthalmic:
      • slit lamp examination
      • tonometry
      • results of computerised visual field plot
  • Other investigations if clinically indicated
    • Cardiac MRI
    • Cardiac stress test
    • CT-KUB
    • Montreal Cognitive Assessment (MOCA)
    • High resolution CT of lungs
  • Management
    • treatment
    • side-effects
  • Proposed monitoring and follow-up plan. Please detail periodic investigations required.

Renewal for Confirmed Disease

CASA requires a report from the doctor monitoring the applicant’s sarcoidosis. CASA will require further reports from other specialists if other organs are involved.  The specialist report should detail:

  • Clinical status
    • symptoms such as breathlessness, pain, palpitations, visual disturbance, neurological symptoms, etc
    • involvement of critical target organs e.g. brain, heart, lungs, kidneys
    • progress
  • Investigations conducted as recommended by specialist, e.g.
    • Pulmonary function test, including spirometry and DLCO
    • Chest x-ray, if clinically indicated
    • Relevant blood tests
    • ECG
    • 24 or 48 hour Holter
    • DAO or CO report with slit lamp examination, tonometry and results of computerised visual field plot
  • Management
    • treatment
    • side-effects
  • Proposed monitoring and follow-up plan

Indicative outcomes

  • Initial notification to CASA and grounding until demonstrated stability and absence of symptoms or complications
  • Unrestricted certification is possible if asymptomatic with absence of or risk of significant impairment



  • Absence of significant symptoms
  • Disease control. (NB Prednisolone equivalent daily dose acceptable at 10mg or less if tolerated)
  • Absence of side-effects from treatment 
  • Absence of cardiac, ocular, neurological or renal involvement


  • Dyspnoea at rest
  • Pulmonary hypertension
  • Any calculi in the collecting system (irrespective of location) or ureteric obstruction
  • Visual disturbance
  • Overlapping visual field defect.
  • Headache, seizure, ataxia, cognitive impairment, etc.
  • Evidence of rhythm disturbance
  • LV ejection fraction <50% or significant abnormality of wall motion on echocardiogram
  • Implantable Cardiac Defibrillator
  • Treatment

Pilot and Controller Information

  • Annual review will be required for a minimum of 3 years after diagnosis (as >50% remission during this period).  Ongoing annual review after 3 years will be dependent upon extent of organ involvement.
  • Multi-crew restriction may be required for pilots
  • An Implantable Cardiac Defibrillator is considered safety relevant.
  • Treatment may impact the ability to exercise the privileges of your medical certificate. Be advised that Prednisolone up to 10mg daily may be acceptable on a case by case basis.


The Clinical Practice Guideline is provided by way of guidance only and subject to the Clinical practice guidelines disclaimer